Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Changed the Study Record Dates label from 'Last Update Posted' to 'Last Update Posted (Estimated)'; this is a minor formatting change that does not affect study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-10-27T21:00:33.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Updated operating-status notice and version 3.2.0; removed version 3.1.0.
    Difference
    2%
    Check dated 2025-10-06T08:11:14.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Added numerous contact phone numbers and the new software revision v3.1.0; removed the old revision v3.0.2. The update primarily signals updated contact options and a version bump.
    Difference
    0.0%
    Check dated 2025-09-29T04:36:07.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Added September 2025 release notes (Revision: v3.0.2) and removed August 2025 notes (Revision: v3.0.1) plus the Back to Top link.
    Difference
    0.4%
    Check dated 2025-09-14T22:07:09.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version, v3.0.1, indicating a recent revision. The previous version, v3.0.0, has been removed from the page.
    Difference
    0.1%
    Check dated 2025-09-07T19:12:17.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    The webpage has been updated to include new facility names and locations, as well as additional drug information for Lenvatinib and Pembrolizumab. Some outdated information has been removed, including previous location details and older drug information.
    Difference
    12%
    Check dated 2025-08-31T12:22:00.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.